Mayne Pharma Group |
High $4.46 |
Low $4.23 |
Trades 1,020 |
Turnover $2,463,536 |
Volume 565,229 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $277,610,112 (439th) |
Close (30-Jun) $4.40 |
Volume (30-Jun) 565,229 |
Shortsold (6-Nov) 1,890,557 (2.31%) (155th) |
|
52w High $6.04 |
52w Low $2.04 |
P/E 263.16 |
EPS 0.31 |
Mayne Pharma to restate US dermatology net revenue for FY22
MYX released this announcement to the ASX on 15 February 2023, 8:10. The announcement is marked as price sensitive, and is 2 page(s) in length and 126.64kb in size.
You can view all announcements from MYX and see how they appear on a price chart on the announcements page.
At the date of this announcement, MYX was 4.650% short sold according to ASIC data. It was ranked the 35th most shorted stock on the ASX. It remains ranked 155th as of the latest reported data (06 November 2026).
| Other Recent Announcements from MYX | |
|---|---|
| Notification of cessation of securities - MYX | 30 June 2023, 16:11 |
| Update - Notification of buy-back - MYX | 30 June 2023, 8:19 |
| Update - Notification of buy-back - MYX | 29 June 2023, 8:20 |
| Mayne Pharma to restate US dermatology net revenue for FY22 | 15 February 2023, 8:10 |
| Notification of cessation of securities - MYX | 25 January 2023, 9:58 |
| Update - Notification of buy-back - MYX | 18 January 2023, 9:21 |
| US launch of HALOETTE, a generic version of NUVARING | 13 January 2023, 8:26 |
If you were already registered, log in here.